Randomised, double-blind, placebo-controlled phase I trial evaluating the safety, tolerability and pharmacokinetics of GNX 5086 in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 29 Aug 2013
Price : $35 *
At a glance
- Drugs GNX 5086 (Primary)
- Indications Myocardial reperfusion injury
- Focus Adverse reactions; Pharmacokinetics
- 29 Aug 2013 New trial record
- 15 Aug 2013 Status changed from not yet recruiting to recruiting. The first volunteer has been enrolled, according to a Congenia media release.
- 24 Jul 2013 Status changed from planning to not yet recruiting. The clinical trial application (CTA) received approval by local regulatory authorities in the Netherlands on 24 July 2013, according to a Congenia media release.